2019

 

MaxCyte to Provide Updates on First-in-class CARMA™ Platform at BIO Investor Forum

October 15, 2019

 

Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines

October 7, 2019

 

MaxCyte to Present Updates on ExPERT™ Platform at Upcoming Conferences

October 2, 2019

 

MaxCyte Presents Updates on First-in-class CARMA™ Platform at Upcoming Meetings

September 30, 2019

 

MaxCyte Announces Presentation at ICLE 2019

September 9, 2019

 

MaxCyte Adds Vice President, Non-Clinical and Translational Studies, to Support Advancement of Programs from Its CARMA™ Platform

July 23, 2019

 

MaxCyte CEO Doug Doerfler to Present at 2019 BIO International Convention

May 29, 2019

 

MaxCyte Progresses Phase I Clinical Trial of Lead mRNA-based Cell Therapy from its CARMA™ Platform

May 8, 2019

 

MaxCyte Presents at 22nd Annual ASGCT Meeting on Manufacturing Process for First CARMA™ Drug Candidate, Including One-Day Cell Processing

May 1, 2019

 

MaxCyte® Launches ExPERT™ Family of Instruments, Providing a Unifying Technology Platform from Concept to Commercialization for the Next Generation of Cellular Therapies

April 8, 2019

 

New Processing Assemblies Deliver Increased Flexibility, Efficiency, and Ease of Cell Recovery

March 29, 2019

 

NK Cells: The Latest Recruits in the Battle Against Cancer

March 29, 2019

 

Don’t Settle for Just Your Average CHO and Other Cell Line Development Advances

March 29, 2019

 

MaxCyte to Present on CARMA™ Platform at Two Upcoming Industry Conferences in Europe

March 18, 2019

 

MaxCyte CEO Doug Doerfler to Present at ARM’s 7th Annual Cell & Gene Therapy Investor Day

March 14, 2019

 

MaxCyte Announces Multi-Drug Clinical & Commercial Agreement with Kite, a Gilead Company

March 1, 2019

 

MaxCyte: Driving New Generation of Cell-Based Medicines

February 6, 2019

 

Hitachi Chemical Advanced Therapeutics Solutions Completes Technology Transfer to Enable Manufacturing of MaxCyte’s CARMA™ Cell Therapy for Clinical Use

February 6, 2019

 

2018

 

MaxCyte to Present on Its CARMA™ Platform During Biotech Showcase™and Phacilitate: Leaders World/World Stem Cell Summit 2019

December 19, 2018

 

MaxCyte to Present at Piper Jaffray 30th Annual Healthcare Conference

November 21, 2018

 

Precision BioSciences and MaxCyte Enter into Clinical and Commercial License Agreement

November 14, 2018

 

CRISPR Therapeutics and MaxCyte Expand Clinical and Commercial License Agreement into Oncology

November 9, 2018

 

MaxCyte to Present on CARMA™ Platform at BIO-EUROPE®

October 30, 2018

 

MaxCyte Commences Dosing in First Clinical Trial in Solid Tumors

October 10, 2018

 

MaxCyte, Inc. to Present on CARMA™ Platform at Two Upcoming Industry Conferences

August 29, 2018

 

MaxCyte Receives US FDA Investigational New Drug Clearance for First Clinical Program

July 16, 2018

 

MaxCyte and U.S. National Institutes of Health’s National Heart, Lung, and Blood Institute Enter Cooperative Research & Development Agreement for Sickle Cell Disease

June 11, 2018

 

MaxCyte, Inc. to Present at 2018 BIO International Convention

May 29, 2018

 

MaxCyte Reports Preclinical Results at ASGCT Annual Meeting Showing Efficient Correction of Sickle Cell Mutation in Hematopoietic Stem Cells (HSC)

May 21, 2018

 

MaxCyte Appoints Dr.Claudio Dansky Ullmann as Chief Medical Officer

April 25, 2018

 

MaxCyte, Inc. to Present at BIO Europe and BIOCapital USA Conferences this Month

March 12, 2018

 

Dr. Richard Douglas Joins MaxCyte Board

February 13, 2018

 

MaxCyte, Inc. to Present at Two Life Sciences Conferences

January 2, 2018

 

2017

 

MaxCyte, Inc. to Present at Phacilitate’s Cell & Gene Therapy Europe Conference

September 14, 2017

 

MaxCyte Appoints Executive Vice President of Global Marketing

August 14, 2017

 

MaxCyte and National Institute of Allergy and Infectious Diseases to Collaborate on Research for Ultra-Rare Disease Therapy

June 7, 2017

 

MaxCyte, Inc. to Present Positive Preclinical Data for Sickle Cell Disease

April 25, 2017

 

CRISPR Therapeutics and Casebia Therapeutics Announce Commercial License Agreement with Maxcyte

March 14, 2017

 

MaxCyte to Present Pre-Clinical CARMA Data at AACR Meeting

March 2, 2017

 

MaxCyte, Inc. to Present at Phacilitate Cell & Gene Therapy World Conference

January 16, 2017

 

MaxCyte, NIH NIAID Study Published in Science Translational Medicine Demonstrates CRISPR-Cas9 Repair of X-linked Chronic Granulomatous Disease (CGD) Gene

January 12, 2017

 

MaxCyte, Inc. to Present Pre-Clinical Data for Targeted Gene-Correction in a Rare Disease at Keystone Symposia on Precision Genome Engineering

January 4, 2017

 

2016

 

MaxCyte Announces Strategic Immuno-Oncology Collaboration to Advance New Generation of CAR-based Cell Therapies

December 21, 2016

 

MaxCyte Appoints Executive Vice President, Business and Strategic Development

November 2, 2016

 

MaxCyte, Inc. to Present at 2016 Cell & Gene Meeting on the Mesa and Biotech Week Boston 2016

September 29, 2016

 

MaxCyte Bolsters Distributor Network in Asia to Meet Growing Market Demands for MaxCyte STX® and MaxCyte VLX® Transfection Systems

September 6, 2016

 

MaxCyte Announces a CRADA with US Army Medical Research Institute of Infectious Diseases for an Exploratory Research Collaboration on Rapid Response Medical Countermeasures

May 17, 2016

 

MaxCyte to Present Gene Editing Results at the American Society of Gene and Cell Therapy Annual Meeting

April 20, 2016

 

MaxCyte Partner to Present Data at the Inaugural Bioprocess International West Conference

March 10, 2016

 

MaxCyte to Present Data on Expression and Functionality of Bispecific Antibodies Produced via Transient Transfection

March 9, 2016

 

MaxCyte Partners to Present Data at Annual Biophysical Society Meeting

February 24, 2016

 

MaxCyte, Inc. to Present at Biotech Showcase 2016

January 7, 2016

 

2015

 

MaxCyte Appoints Spinco Biotech Pvt Ltd. as Distributor in India for the MaxCyte STX® and MaxCyte VLX®

October 20, 2015

 

MaxCyte to present novel approach to CAR-T for treatment of solid tumors at Biochemical Society in London

October 19, 2015

 

MaxCyte, Inc. to Present at 2015 Immuno-Oncology Conference

September 30, 2015

 

MaxCyte to Present New Data on Expression and Functionality of Bispecific Antibodies Produced via Transient Transfection

September 22, 2015

 

MaxCyte Appoints Chayon Laboratories as Distributor in Korea for the MaxCyte STX® and MaxCyte VLX®

September 15, 2015

 

MaxCyte to Present Data on the Ability of Flow Electroporation to Streamline Antibody Development and Production

August 3, 2015

 

MaxCyte Awarded Maryland Stem Cell Research Fund Grant

June 11, 2015

 

MaxCyte to Present Data on Development of ‘Enhanced’ Potency Cell Therapy Products

May 19, 2015

 

MaxCyte and Partners to Present Data at American Society of Gene and Cell Therapy Meeting

May 6, 2015

 

MaxCyte to Present Data on Achieving 2.7 grams/Liter of Antibody in CHO Cells With Flow Electroporation

May 5, 2015

 

MaxCyte Appoints Cold Spring Biotech Corp. as Distributor in China, Taiwan, and Hong Kong for the MaxCyte STX® and MaxCyte VLX®

April 27, 2015

 

MaxCyte and The Johns Hopkins Kimmel Cancer Center Announce Strategic Immuno-Oncology Collaboration to Advance CAR T-cell Therapies

April 21, 2015

 

MaxCyte to Present at the 2015 Jefferies Immuno-Oncology Summit

April 15, 2015

 

MaxCyte Publishes Data on Gram/Liter Antibody Production in the Journal of Biomolecular Screening

March 31, 2015

 

MaxCyte to Present at 3rd Annual Regen Med Investor Day

March 24, 2015

 

MaxCyte to Present Data Demonstrating the Impact of Flow Transfection on Improving Protein Expression

January 19, 2015

 

2014

 

MaxCyte Appoints Executive Vice President of Global Sales

October 15, 2014

 

Accelerating Product Development: From Transient Transfection to Stable Pools and Stable Clones

May 13, 2014

 

MaxCyte Introduces Rapid, Automated, Scalable Flow Electroporation-based Technology for Vaccine Development

March 20, 2014

 

MaxCyte Introduces the 2014 MaxCyte STX® Scalable Transfection System at CHI’s 13th Annual PepTalk Conference in Palm Springs, Booth #308

January 13, 2014